Trials / Terminated
TerminatedNCT02074410
Safety and Efficacy of OMS643762 in Subjects With Huntington's Disease
Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety and Efficacy of OMS643762 in Subjects With Huntington's Disease
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Omeros Corporation · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety, tolerability and pharmacokinetics of OMS643762 (the study drug) in subjects with Huntington's disease (HD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | OMS643762 | |
| DRUG | Placebo |
Timeline
- Start date
- 2014-01-01
- Primary completion
- 2014-10-15
- Completion
- 2014-10-15
- First posted
- 2014-02-28
- Last updated
- 2018-10-22
Locations
9 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02074410. Inclusion in this directory is not an endorsement.